ArticleScientific reports2026
Association of ABCG2 gene variants with urate levels in Mexican patients with type 2 diabetes and chronic kidney disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The contribution of ABCG2 gene variants to hyperuricemia in Mexican patients with type 2 diabetes (T2D) remains uncertain, despite previously established associations in other populations. In this study, we analyzed the association of the ABCG2 gene variants rs2054576, rs2231142 and rs1001796 with serum uric acid (SUA) levels and hyperuricemia in patients with T2D and chronic kidney disease (CKD) from Mexico. This cross-sectional study involved the genotyping of 1,085 Mexican patients with T2D and 284 healthy subjects (HS) for the missense variant Q141K (rs2231142) and two intronic variants, rs2054576, and rs10011976 of the ABCG2 gene. Univariate and multivariate analyses were conducted to examine the association between ABCG2 genotypes and urate levels and hyperuricemia in relation to the presence of CKD. Clinical and biochemical parameters were also determined and compared. Serum uric acid concentrations and prevalence of hyperuricemia were higher in the patient group compared to healthy subjects. In the patient population, individuals with CKD demonstrated elevated SUA levels and a greater prevalence of hyperuricemia when compared to those without CKD (6.4 mg/dL vs. 5.0 mg/dL, p < 0.001 and 49% vs. 19%, p < 0.001), respectively). The rs2231142 variant showed a significant association with SUA concentrations among patients with T2D (β = 0.393; p = 0.017), as well as healthy individuals (β = 0.407; p = 0.005); however, no significant association was observed with hyperuricemia. In this cohort of Mexican patients with T2D, kidney disease was found as the primary factor associated with hyperuricemia. Additionally, rs2231142 was the only ABCG2 gene variant linked to SUA levels in both T2D patients and healthy individuals, though it was not associated with hyperuricemia. Nevertheless, genetic analysis of rs2231142 may contribute to the evaluation of T2D patients at risk for complications related to elevated uric acid.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.